Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Crolibulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 0.70 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 0.70 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 0.70 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 0.70 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 0.70 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 0.70 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 0.70 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 0.70 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 0.70 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 0.70 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 0.70 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 0.70 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 0.70 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 0.70 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 3/20 | 0.70 |
| ▸ | MYB | P10242 | 13/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crolibulin SCHEMBL1750915 | 1.00 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Crolibulin SCHEMBL1750454 | 1.00 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Crolibulin SCHEMBL1750575 | 1.00 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Crolibulin SCHEMBL29385790 | 1.00 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5959431 | 0.92 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5729902 | 0.90 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5728917 | 0.90 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19732221 | 0.90 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14319090 | 0.88 | MYB (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4326758 | 0.87 | TUBB4A (0.69) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773592-B1 | NOVEL COMBINATIONS OF A TUBULIN POLYMERIZATION INHIBITOR AND A POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR FOR USE IN THE TREATMENT OF CANCER | NOVIGA RES AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-11590130-B2 | Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer | NOVIGA RESEARCH AB (SE) | 2023-02-28 | — | — | US | disclosed |
| US-11291630-B2 | Gelling compositions for treating malignant tumours and/or preventing tumour recurrence | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2022-04-05 | — | — | US | disclosed |
| CN-112755188-B | Application of SHMT2 inhibitor in preparation of medicines for inhibiting growth and metastasis of bladder cancer cells | 中国科学院微生物研究所 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590130-B2 | Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer | PARP1, PARP2, PARP11 | TUBB4A 21/4885TUBB 15/4885TUBA3C 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.